Smoking Cessation Treatment With Transdermal Nicotine Replacement Therapy - 1

This study has been completed.

First Received: August 12, 2003 Last Updated: June 17, 2009 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	New York University School of Medicine
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00067158

Purpose

The purpose of this study is to look at how feasible it is to incorporate a state-of-the-art smoking cessation treatment program into community substance abuse treatment programs and its impact on substance abuse and cigarette smoking.

Condition	Intervention	Phase
Tobacco Use Disorder	Drug: nicotine transdermal system	Phase III

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Smoking Cessation Treatment With Transdermal Nicotine Replacement Therapy

Resource links provided by NLM:

MedlinePlus related topics: Quitting Smoking Smoking

Drug Information available for: Nicotine tartrate Nicotine polacrilex

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Drug use
Smoking Cessation

Estimated Enrollment:	585
Study Start Date:	April 2003
Study Completion Date:	July 2004
Primary Completion Date:	July 2004 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patient is alcohol or drug dependent, in Outpatient Drug-Free or Opiate Substitute program and is interested in quitting smoking

Exclusion Criteria:

Patient is psychotic
Use of smokeless tobacco
Use of other smoking cessasation product
Pregnancy
Patient has hyper-tension, heart problems, or skin condition

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00067158

Locations

United States, California
Matrix Institute on Addictions
Los Angeles, California, United States, 90016
Tarzana Treatment Center
Tarzana, California, United States, 91356
United States, Florida
Center for Drug Free Living
Orlando, Florida, United States, 32805
SPECTRUM
Miami, Florida, United States, 33156
United States, Michigan
Chelsea Arbor Addictions Treatment Center
Ann Arbor, Michigan, United States, 48103
Psychiatry and Behavioral Medicine Professionals I
Detroit, Michigan, United States, 48207
United States, New York
Mount Sinai Medical Center
New York, New York, United States, 10029
Narco Freedom (Bridge Plaza)
Long Island City, New York, United States, 11101
St. Luke's Roosevelt Hospital Center
New York, New York, United States, 10019
St. Luke's Roosevelt Hospital Center, Womens
New York, New York, United States, 10025
United States, North Carolina
Coastal Horizons Center, Inc.
Wilmington, North Carolina, United States, 28412
Piedmont Behavioral Healthcare
Concord, North Carolina, United States, 28001
United States, South Carolina
Behavioral Health Services of Pickens County
Pickens, South Carolina, United States, 29671

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

New York University School of Medicine

Investigators

Principal Investigator:

Malcolm Reid, Ph.D.

New York University

More Information

Additional Information:

Data Elements This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers:	NIDA-CTN-0009-1
Study First Received:	August 12, 2003
Last Updated:	June 17, 2009
ClinicalTrials.gov Identifier:	NCT00067158 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Nicotine polacrilex
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Cholinergic Agonists
Tobacco Use Disorder
Nicotinic Agonists
Physiological Effects of Drugs
Disorders of Environmental Origin
Central Nervous System Stimulants
Cholinergic Agents

Pharmacologic Actions
Mental Disorders
Nicotine
Autonomic Agents
Therapeutic Uses
Substance-Related Disorders
Ganglionic Stimulants
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on November 27, 2009